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Tumorigenesis and Neoplastic Progression
Snail Family Transcription Factors Are Implicated in
Thyroid Carcinogenesis
Robert G. Hardy,* Carolina Vicente-Duen˜as,†
Ines Gonza´lez-Herrero,† Catriona Anderson,‡
Teresa Flores,§ Sharon Hughes,¶ Chris Tselepis,¶
James A. Ross,* and Isidro Sa´nchez-Garcı´a†
From the Tissue Injury and Repair Group,* Centre for
Regenerative Medicine, University of Edinburgh, Edinburgh,
United Kingdom; the Department of Pathology,‡ Royal Infirmary
of Edinburgh, Edinburgh, United Kingdom; the Cancer Research
United Kingdom Institute for Cancer Studies,¶ University of
Birmingham, Birmingham, United Kingdom; and the
Experimental Therapeutics and Translational Oncology
Program,† Instituto de Biologı´a Molecular y Celular del Ca´ncer,
and the Pathology Department,§ Consejo Superior de
Investigaciones Cientificas/Universidad de Salamanca,
Salamanca, Spain
E-Cadherin (CDH1) expression is reduced in thyroid
carcinomas by primarily unknown mechanisms. In
several tissues, SNAIL (SNAI1) and SLUG (SNAI2) in-
duce epithelial-mesenchymal transition by altering
target gene transcription, including CDH1 repression,
but these transcription factors have not been studied in
thyroid carcinoma. Recently, our group has provided
direct evidence that ectopic SNAI1 expression induces
epithelial and mesenchymal mouse tumors. SNAI1,
SNAI2, and CDH1 expression were analyzed in thyroid-
derived cell lines and samples of human follicular and
papillary thyroid carcinoma by reverse transcriptase-
polymerase chain reaction, Western blotting, and im-
munohistochemistry. The effect of SNAI1 expression on
CDH1 transcription was analyzed by reverse transcrip-
tase-polymerase chain reaction and Western blotting in
ori-3 cells. Thyroid carcinoma development was ana-
lyzed in CombitTA-Snail mice, in which SNAI1 levels are
up-regulated. SNAI1 and SNAI2 were not expressed in
cells derived from normal thyroid tissue, or in normal
human thyroid samples, but were highly expressed in
cell lines derived from thyroid carcinomas, in human
thyroid carcinoma samples, and their metastases.
SNAI1 expression in ori-3 cells repressed CDH1 tran-
scription. Combi-TAmice developed papillary thyroid
carcinomas, the incidence of which was increased by
concomitant radiotherapy. In conclusion, SNAI1 and
SNAI2 are ectopically expressed in thyroid carcino-
mas, and aberrant expression in mice is associated
with papillary carcinoma development. (Am J Pathol
2007, 171:1037–1046; DOI: 10.2353/ajpath.2007.061211)
Thyroid cancer consists of several histological subtypes,
including follicular and papillary carcinoma. These two his-
tiotypes exhibit both common and individual alterations in
gene expression compared with normal thyroid tissue. At
the molecular level, alterations in expression of various pro-
teins have been found between normal and tumor tissue
including growth factors, eg, transforming growth factor-1,
epidermal growth factor; proteins regulating the cell cycle
and apoptosis, eg, retinoblastoma, cyclin D1; cell adhesion
molecules, such as E-cadherin (CDH1) and CD44; and
tyrosine kinases and their receptors, eg, RET.1
Cadherins are transmembrane proteins mediating ho-
motypic cell-cell adhesion. At a cellular level their expres-
sion induces differentiation and growth suppression,
which translates at an organ level into the formation of
polarized, ordered tissues.2 The prototypical member,
CDH1, is highly expressed in the normal thyroid gland
and in benign thyroid lesions, including toxic diffuse goi-
ter, multinodular goiter, and follicular adenomas.3 CDH1
expression leads to aggregation of thyrocytes in culture,4
and exposure of thyrocytes to thyroid-stimulating hor-
mone increases CDH1 transcription,5 demonstrating the
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intimate relationship between CDH1 expression and thy-
roid differentiation.
CDH1 expression is decreased in classic papillary
thyroid carcinoma3,6–10 and its diffuse sclerosing variant9
and also in follicular carcinoma.3,7,8,11–13 Rarely, this de-
crease in expression is attributable to mutation of the
CDH1 gene,7,9 loss of heterozygosity,7 or hypermethyl-
ation of the CDH1 promoter.9 In most tumors the mech-
anism of CDH1 down-regulation is, however, unknown.
Several transcriptional repressors have been shown to
modulate cadherin expression, including Snail family
members SNAIL (SNAI1)14,15 and SLUG (SNAI2).16,17
These transcription factors contain zinc finger motifs and
bind to E-boxes in the CDH1 promoter, repressing gene
transcription14,15 and producing changes in cell pheno-
type consistent with epithelial to mesenchymal transition
including migration, invasion, resistance to cell death,
and induction of angiogenesis.18
SNAI1 and SNAI2 are ectopically expressed in several
tumor cell lines.14 Furthermore, SNAI1 has been found to
be expressed in a number of human tumors derived from
epithelial tissues, including gastric and hepatic carci-
noma,19–21 with expression in the latter correlating with
both tumor invasiveness and prognosis.20,21 Recently,
we provided the first direct experimental evidence that
SNAI1 was linked to tumorigenesis by showing that mice
in which SNAI1 was overexpressed by 20% developed
both epithelial and mesenchymal tumors.22 Embryonic
fibroblasts derived from these mice were subsequently
shown to induce tumor formation in nude mice.22
We sought to investigate the pattern of SNAI1 and
SNAI2 expression in the normal human thyroid gland,
papillary and follicular thyroid cancers, and transformed
lines derived from thyroid carcinomas. We subsequently
examined the effects of SNAI1 expression in thyroid cells
and analyzed thyroid carcinoma development in mice
overexpressing SNAI1.
Materials and Methods
Human Tissue Specimens
Formalin-fixed, paraffin-embedded sections of follicular
thyroid carcinoma (n  31) and papillary thyroid carci-
noma (n  32) were obtained from the pathology ar-
chives of the Royal Infirmary of Edinburgh, Edinburgh,
UK, and University Hospital Birmingham, Birmingham,
UK. Sections of formalin-fixed normal human skin and
colorectal and prostate carcinomas were used as posi-
tive and negative tissue controls for immunohistochemis-
try. Ethical approval was obtained for the use of all human
material (LREC reference 04/S1101/59). Pathological
stage of tumors used was as follows: follicular: minimally
invasive, n 17; invasive, n 14; papillary: T1, n 6; T2,
n  11; T3, n  5; T4, n  10.
Antibodies, Tissue Culture, and Plasmids
Primary antibodies were as follows. CDH1 antibody
(clone 36) was obtained from BD Biosciences, Oxford,
UK, and used at a concentration of 1:300 for immuno-
histochemistry, 1:300 for immunofluorescence, and
1:5000 for Western blotting. SNAI1 and SNAI2 antibod-
ies and specific blocking peptides were obtained from
Autogen Bioclear, Wiltshire, UK. SNAI1 (clone E18)
was used at a dilution of 1:10 for immunohistochemis-
try, 1:50 for immunofluorescence, and 1:100 for West-
ern blotting. SNAI2 (clone G18) was used at 1:20 for
immunohistochemistry, 1:50 for immunofluorescence, and
1:100 for Western blotting. Monoclonal anti-SNAI1 antibody
was a gift from Antonio Garcia Herreros (Unitat de Biologia
Cellular i Molecular, Barcelona, Spain) and has been previ-
ously described23 and was used at 1:1000 for Western blot-
ting. Mouse monoclonal anti--actin (clone AC-15) was ob-
tained from Abcam (Cambridge, UK) and used at 1:10,000
in Western blotting. Secondary antibodies were as follows:
goat anti-mouse IgG-horseradish peroxidase-conjugated
(Upstate, Dundee, Scotland) and rabbit anti-goat IgG-
horseradish peroxidase-conjugated (Autogen Bioclear)
were used at 1:5000 for Western blotting. Fluorescein iso-
thiocyanate-linked anti-mouse IgG2a (Sigma, Gillingham,
UK) was used at a 1:800 dilution and fluorescein isothio-
cyanate-linked rabbit anti-goat IgG (Sigma) was used at a
1:200 dilution, both for immunofluorescence.
K1 and ori-3 cells were a gift from Professor D.
Wynford-Thomas, Department of Pathology, University
of Cardiff, Cardiff, UK. B-CPAP, CAL-62, FTC-133, and
8305C cells were a gift from Professor M. d’Armiento,
Department of Experimental Medicine and Pathology,
University of Rome “La Sapienza,” Rome, Italy. Lines
were derived from the following human tissues: ori-3,
SV40-transformed normal thyrocytes; B-CPAP, K1,
papillary thyroid carcinoma; FTC-133, follicular thyroid
carcinoma; CAL-62, 8305C, anaplastic thyroid carci-
noma. Culture media for individual lines was as follows:
B-CPAP, K1, ori-3, 8305C, RPMI 1640 medium  10%
fetal calf serum; CAL-62, Dulbecco’s modified Eagle’s
medium  5% fetal calf serum; FTC-133, Dulbecco’s
modified Eagle’s medium  Ham’s F12 (1:1)  10% fetal
calf serum  2 mmol/L glutamine. All culture media, se-
rum, and glutamine were purchased from Life Technolo-
gies, Paisley, UK, and lines were maintained in a 5% CO2
humidified atmosphere at 37°C. The plasmid pCAG-hS-
nail was a gift from Professor S. Tsukita, Department of
Cell Biology, University of Kyoto, Kyoto, Japan, and has
been described previously.24
Cell Transfection, RNA Extraction,
and cDNA Formation
To prepare for transfection, 2 105 cells were cultured in
six-well plates 12 hours before transfection. Cells were
then transfected with the plasmid pCAG-hSnail using
Fugene 6 reagent (Roche Diagnostics, Lewes, UK) at a
plasmid/DNA ratio of 3:2, according to the manufactur-
er’s instructions. Cells were separated from the culture
dish by scraping 24 hours after transfection, and RNA
was harvested using TRIzol reagent (Invitrogen, Paisley,
UK) according to the manufacturer’s protocol. cDNA was
produced using a reverse transcription kit (Promega,
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Southampton, UK) after prior treatment of RNA with 1 U of
DNase (Promega) per reaction with incubation at 37°C for
30 minutes. Synthesized cDNA was used in subsequent
polymerase chain reactions. Cell transfection experiments
were performed on three separate occasions, after initial
transfection efficiencies of 70 to 80% were documented in
ori-3 cells.
Total RNA from mice was isolated in two steps using
TRIzol (Life Technologies, Inc., Grand Island, NY) fol-
lowed by RNeasy mini-kit (Qiagen Inc., Valencia, CA)
purification following the manufacturer’s protocols.
RNA was cleaned up with the optional on-column DNase
treatment. The integrity and quality of RNA were verified by
electrophoresis, and RNA concentration was measured. To
analyze expression of CombitTA-Snail in mice, reverse tran-
scriptase (RT) was performed according to the manufac-
turer’s protocol in a 20-l reaction containing 50 ng of
random hexamers, 3 g of total RNA, and 200 U of Super-
script II RNase H reverse transcriptase (Gibco/BRL,
Paisley, UK).
Polymerase Chain Reaction
Oligonucleotides (TAGN, Gateshead, UK) used for am-
plification from cell lines and polymerase chain reaction
(PCR) conditions were as follows, with an initial denatur-
ation step of 94°C for 5 minutes in all cases. CDH1:
forward 5-TGCCCAGAAAATGAAAAAGG-3, reverse 5-
GTGTATGTGGCAATGCGTTC-3, with 35 cycles of 94°C
30 seconds, 58°C 1 minute, and 72°C 1 minute. SNAI1:
forward 5-AATCGGAAGCCTAACTACAAG-3, reverse 5-
AGGAAGAGACTGAAGTAGAG-3 with 35 cycles of
94°C  1 minute, 53°C  1 minute, and 72°C  1 minute.
SNAI2: forward 5-GCCTCCAAAAAGCCAAACTA-3, re-
verse 5-CACAGTGATGGGGCTGATG-3 with 35 cycles of
94°C  1 minute, 53°C  1 minute, and 72°C  1 minute.
PCR reagent (Promega) concentrations per reaction were
as follows: oligonucleotides, 25 pmol; MgCl2, 15 mmol/L;
and Taq polymerase, 2 U.
To analyze expression of CombitTA-Snail in mice, re-
verse transcription was performed according to the man-
ufacturer’s protocol in a 20-l reaction containing 50 ng
of random hexamers, 3 g of total RNA, and 200 U of
Superscript II RNase H reverse transcriptase (Gibco/
BRL). Exogenous SNAI1 gene product expression in
mice was analyzed with mSnailF and Combi-polyA-B1
primers: Combi-polyA-B1: 5-TTGAGTGCATTCTAGTT-
GTG-3; mSnailF: 5-CAGCTGGCCAGGCTCTCGGT-3.
The PCR conditions used to amplify CombitTA-Snail were
as follows: 94°C  1 minute, 56°C  1 minute, and
72°C  2 minutes for 40 cycles. Mouse E-cadherin ex-
pression was analyzed with the following primers: mEc-
adherin forward: 5-GGACGTCCATGTGTGTGA-3; mEc-
adherin reverse: 5-CTTCTACACACTCAGGGA-3. The
PCR conditions used to amplify E-cadherin were as fol-
lows: 94°C  1 minute, 52°C 1 minute, and 72°C  2
minutes for 40 cycles. The PCR products were confirmed
by hybridization with specific internal probes. Amplifica-
tion of -actin RNA served as a control to assess the
quality of each RNA sample from both cell lines and mice.
Immunohistochemistry for SNAI1, SNAI2,
and CDH1
Immunohistochemistry for CDH1 was performed as follows.
Sections were dewaxed, incubated in methanol:hydrogen
peroxide (H2O2) (10:1) for 5 minutes, and antigen retrieval
was performed in 0.01 mol/L sodium citrate three times for
5 minutes each in a microwave. Sections were incubated in
normal goat serum for 30 minutes and then in primary
antibody for 60 minutes. After washing in Tris-buffered sa-
line (TBS) sections were incubated in horseradish peroxi-
dase Envision solution (DAKO, Ely, UK) for 60 minutes.
Diaminobenzidine tetrahydrochloride (DAKO) was then
used as a substrate for the peroxidase reaction at a con-
centration of 1 mg/ml  1 l/ml H2O2, and slides were
dipped in hematoxylin, dehydrated, and mounted.
Immunohistochemistry for SNAI1 and SNAI2 was per-
formed as follows. Slides were immersed in W-cap buffer
(Bio-Optica, Milan, Italy) and cycled in a Pixel antigen re-
triever (CellPath, Newtown, UK) for 60 minutes, washed in
running water, and placed in methanol/hydrogen peroxide
(10:1) for 5 minutes. Sections were then incubated in pri-
mary antibody in TBS 7.5  buffer (Bios Europe Ltd., Skel-
mersdale, UK) at 4°C overnight, washed with TBS, and
reacted with peroxidase-linked rabbit anti-sheep antibody
(DAKO) at a 1:100 dilution in TBS for 1 hour. The immuno-
reactivity was revealed as above using diaminobenzidine
tetrahydrochloride. Slides were then dipped in hematoxylin,
dehydrated, and mounted. To control for SNAI1 and SNAI2
antibody specificity, primary antibodies were combined
with a 10-fold excess of blocking peptide, incubated for 2
hours at room temperature, and then used as previously
described for immunohistochemistry.
Intensity and subcellular localization of reactivity was
scored as previously described.25 In brief, intensity of
staining (graded 0 to 3) and percentage of positively
staining follicles per lesion, subcellular localization of
immunoreactivity, and correlation between positive im-
munoreactivity, tissue phenotype/morphology, and local-
ization within tumor (ie, centrally or at invasive front) were
recorded. The presence of morphologically normal folli-
cles within each section served as additional internal
negative/positive controls depending on antibody used.
Correlation of staining with tumor characteristics was as-
sessed using Fisher’s exact test.
Immunofluorescence for SNAI1, SNAI2,
and CDH1
Cells were grown on coverslips, and then immunofluores-
cence was performed on confluent cells as described.
Cells were washed with phosphate-buffered saline (PBS),
fixed with ice-cold methanol/acetone (1:1 ratio) for 5 min-
utes, and then washed with PBS. Cells were treated with
a 0.1% solution of Triton-X for 20 minutes then blocked
with a 5% solution of normal goat serum for 20 minutes.
Primary antibodies were constituted in 5% normal goat
serum and applied for 1 hour; secondary antibody was
used for 30 minutes, with multiple washes with 1% bovine
serum albumin after both primary and secondary antibody
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stages. 4,6-Diamidino-2-phenylindole (DAPI) (Sigma) was
used at a concentration of 1:10,000 for 1 minute to stain
nuclei. Coverslips were then mounted onto slides with im-
munofluorescence mounting media (Sigma). A Leica fluo-
rescence microscope (Leica, Wetzlar, Germany) was used
to analyze sections.
Protein Lysate Formation and Western Blotting
Protein lysates were made from cell lines by washing in
PBS then lysing in radioimmunoprecipitation assay buffer
containing protease inhibitors (Sigma). Protein concen-
trations were determined using a Bio-Rad protein assay
kit (Bio-Rad, Hemel Hempstead, UK). For Western blot-
ting, equal concentrations of protein lysates were sepa-
rated on 8% (CDH1) or 15% (SNAI1 and SNAI2) sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gel, and proteins were transferred onto Hybond
polyvinylidene difluoride nitrocellulose membrane (Amer-
sham, High Wycombe, UK). Membranes were blocked in
10% Marvel in TBS for 20 minutes and then incubated with
primary antibodies in TBS-Tween at 4°C overnight. Blots
were washed extensively with TBST, probed with second-
ary antibody, washed in TBS-Tween, and reacted with en-
hanced chemiluminescence reagent (Amersham) accord-
ing to the manufacturer’s instructions.
Mice and Treatments
Animals were housed under nonsterile conditions in a
conventional animal facility. CombitTA-Snail mice have
been previously described.22 Similar phenotypic features
were seen in all assays for both of the CombitTA-Snail
transgenic lines generated. To study the effect of irradi-
ation on thyroid carcinoma development, 30 CombitTA-
Snail and 30 control mice 5 to 6 weeks of age were
irradiated with a dose of 400 rads and maintained in
microisolator cages on sterilized food and acidified ster-
ile water.
For the effect of SNAI1 suppression in thyroid carcino-
mas after radiation treatment, stock solutions of 4 mg/ml
doxycycline (Sigma) were prepared fresh in water and
sucrose and administered to mice in the drinking water.
Mice were started on doxycycline or placebo (the same
volume of diluent) beginning on the day after thyroid
carcinoma was confirmed (day 0). Mice tolerated the
treatment well, and no interruption of therapy was neces-
sary. Mice were followed clinically three times a week.
The death endpoint was determined either by spontane-
ous death of the animal or by elective sacrificing of the
animal because of signs of pain or suffering according to
established criteria.
Histological Analysis of Mice
Mice included in this study were subjected to standard
necropsy. All major organs were closely examined under
the dissecting microscope, and samples of each organ
were processed into paraffin, sectioned, and examined
histologically. All tissue samples were taken from homog-
enous and viable portions of the resected sample by the
pathologist and were fixed within 2 to 5 minutes of exci-
sion. Hematoxylin and eosin (H&E)-stained sections of
each tissue were reviewed by a single pathologist (T.F.).
For comparative studies, age-matched mice were used
(wild-type or CombitTA-Snail mice in the continuous pres-
ence of tetracycline). Statistical analysis of rates of tumor
development in wild type compared with CombiTA-Snail
mice was analyzed using Fisher’s exact test.
Cell Transfers and Tumorigenicity Assay
To test the tumorigenicity of the various CombitTA-Snail
thyroid cancers, 4- to 6-week-old athymic (nude) male
mice were injected subcutaneously on both flanks with
106 cells suspended in 200 l of PBS. The animals were
examined for tumor formation once a week and were
sacrificed for histopathological studies and collection of
tissues for DNA analyses when moribund.
Results
SNAI1 and SNAI2 mRNA and Protein Are
Expressed in Thyroid Carcinoma Cell Lines
To test the initial hypothesis that Snail family transcription
factors would be expressed in thyroid carcinoma, a panel
of human thyroid cell lines were screened for SNAI1 and
SNAI2 mRNA expression by reverse transcription-poly-
merase chain reaction (RT-PCR) and protein expression
by Western blot. As can be seen from Figure 1, A and B,
all lines expressed both SNAI1 and SNAI2 mRNA and
protein except ori-3 cells, the only line tested that does
not originate from a thyroid carcinoma. These data there-
fore support the hypothesis that SNAI1 and SNAI2 are
aberrantly transcribed in thyroid carcinoma. The expres-
sion of CDH1 mRNA and protein was also analyzed in
these lines. Ori-3 cells expressed abundant CDH1 mRNA
and protein, as may be anticipated, whereas B-CPAP
and FTC-133 cells demonstrated weaker CDH1 mRNA
and protein expression. No CDH1 mRNA or protein ex-
pression was seen in lines CAL-62, 8305C, and K1.
We next analyzed whether the morphology of cultured
cells expressing SNAI1 and SNAI2 was different from
ori-3 cells, which do not express these proteins. All lines
expressing SNAI1 and SNAI2 demonstrated a lack of
close cellular contact, even at confluence (Figure 1C),
compared with ori-3 cells that grew as a cell monolayer
with close apposition of cells at confluence (Figure 1E).
For SNAI1 and SNAI2 protein to be functional in thyroid
tumor cell lines, they would be expected to show nuclear
localization. We therefore used immunofluorescence to
study this, with counterstaining of nuclei with DAPI, a
nuclear marker. SNAI1 and SNAI2 were predominantly
localized to cell nuclei, with weaker cytoplasmic reactivity
(Figure 1, E and F, respectively), as shown by co-local-
ization with DAPI. Thus SNAI1 and SNAI2 are localized to
the nuclei in the thyroid carcinoma cells analyzed, and
their presence correlates with alterations in cell morphol-
ogy expected for cells with impaired cell-cell adhesion.
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SNAI Expression Is Associated with Modulation
of CDH1 Expression in Thyrocytes in Vitro
We next assessed whether expression of SNAI1 in ori-3
cells leads to a modulation in CDH1 mRNA and protein
levels. The plasmid pCAG-hSnail was used to express tran-
siently human SNAI1 in ori-3 cells, and CDH1 mRNA and
protein levels were assessed before transfection and 24
hours after transfection by RT-PCR on extracted RNA or
Western blotting of protein lysates. As can be seen, CDH1
mRNA (Figure 2A) and protein (Figure 2B) were present in
untransfected ori-3 cells, but expression of SNAI1 re-
pressed both CDH1 mRNA (Figure 2A) and protein (Figure
2B) to an undetectable level at 24 hours. This demonstrates
that SNAI1 seems to be active in ori-3 thyrocytes with re-
spect to repression of CDH1 transcription.
SNAI1 and SNAI2 Are Expressed in Human
Thyroid Carcinomas
Antibodies to SNAI1 and SNAI2 were initially character-
ized. Strong nuclear staining in colorectal adenocarcino-
mas was seen with antibodies to both SNAI1 (Figure 3A)
and SNAI2 (Figure 3B), as has been previously shown.26
Figure 1. Expression of SNAI1, SNAI2, and CDH1 in thyroid-derived cell
lines. cDNA (A) and protein (B) expression of SNAI1, SNAI2, and CDH1 in
thyroid lines were analyzed by RT-PCR with products resolved on 2% agarose
gels (for cDNA) and protein electrophoresis on 8% SDS-PAGE gels (for
CDH1) and 15% SDS-PAGE gels (for SNAI1 and SNAI2). -Actin amplification
was used to ensure equal sample loading. Positive controls were LNCaP cells
(SNAI1, SNAI2) and MCF-7 cells (CDH1). Negative controls were reactions
without cDNA. Antibodies E18 and G18, already described, were used in
Western blotting for SNAI1 and SNAI2, respectively. SNAI1 and SNAI2 cDNA
and protein were expressed in all lines derived from thyroid carcinomas
(B-CPAP, CAL-62, FTC-133, K1, and 8305C) but not in ori-3 cells derived from
normal thyrocytes. CDH1 cDNA and protein was strongly expressed in ori-3
cells, with weaker expression in B-CPAP and FTC-133 cells. Cell lines ex-
pressing SNAI1 and SNAI2 did not form monolayers with close cell contacts,
even at confluence, illustrated by the gaps between 8305C cells (C, arrows).
Ori-3 cells did, however, form a confluent monolayer without discernable
gaps between cells (D, arrows). Both SNAI1 and SNAI2 demonstrated a
mixture of nuclear and cytoplasmic localization in all cell lines in which they
were expressed, with nuclear staining being much more intense, as shown
by colocalization of SNAI1 and SNAI2 (fluorescein isothiocyanate) with DAPI
nuclear marker (blue) (E and F, respectively, nuclear localization demon-
strated by arrows, FTC-133 cells shown). Original magnifications: 20 (C
and D); 60 (E and F).
Figure 3. Characterization of antibodies to SNAI1 and SNAI2. Positive reac-
tivity is demonstrated by brown staining. SNAI1 (A) and SNAI2 (B) demon-
strate nuclear reactivity in colorectal adenocarcinoma. Omission of second-
ary antibody leads to an absence of SNAI staining (C) compared with sections
where secondary antibody is used (D). Use of a specific blocking peptide to
SNAI1 antibody similarly produces an absence of staining (E) compared with
sections stained in the absence of blocking peptide (F) (arrows indicate
nuclear staining). Identical results were obtained for SNAI2 antibody with
omission of secondary antibody and use of blocking peptide. Original mag-
nifications, 40.
Figure 2. Effect of transfection of SNAI1 on CDH1 expression in thyrocytes.
Ori-3 cells were transfected with SNAI1; CDH1 and SNAI1 cDNA expression
was analyzed by RT-PCR 24 hours after transfection (A), and protein expres-
sion was analyzed by electrophoresis on 8% SDS-PAGE gels (for CDH1) and
15% SDS-PAGE gels (for SNAI1) (B). -Actin amplification was used to
ensure equal sample loading. Positive controls were LNCaP cells (SNAI1) and
MCF-7 cells (CDH1). Negative controls were reactions without cDNA. At 24
hours after transfection, SNAI1 cDNA and protein are expressed, associated
with transcriptional silencing of CDH1 and corresponding loss of cDNA and
protein expression.
SNAI1 and Thyroid Cancer 1041
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Omission of secondary antibody led to an absence of
immunoreactivity (Figure 3C), compared with when sec-
ondary antibody was used (Figure 3D). Addition of a
specific SNAI1- or SNAI2-blocking peptide to the primary
antibody similarly led to a lack of staining (Figure 3E)
compared with reactions without blocking peptide (Fig-
ure 3F). Follicular (n  31) and papillary (n  32) thyroid
carcinomas were then stained for SNAI1, SNAI2, and
CDH1. Expression of these proteins was also analyzed in
morphologically normal areas of thyroid tissue in each
section.
Immunoreactivity for neither SNAI1 nor SNAI2 was
seen in morphologically normal follicles in any specimen
analyzed (Figure 4, A and B); thus SNAI1 and SNAI2 are
not expressed in normal thyroid tissue. Histologically nor-
mal thyroid gland demonstrated CDH1 reactivity along
epithelial cell membranes, as has been previously de-
scribed,3 in all cases (Figure 4C).
SNAI1 was expressed in neoplastic areas of 18 of 31
follicular carcinomas. On analysis of expression by tumor
stage, SNAI1 was expressed in 9 of 17 minimally invasive
and 9 of 14 invasive lesions. There was therefore no
correlation of SNAI1 expression with tumor stage (P 
0.39). Reactivity was seen in nuclear and cytoplasmic
localizations in positively staining cases (Figure 4, D and
G). SNAI2 reactivity was seen in 22 of 31 follicular carci-
nomas, 12 of 17 minimally invasive, and 10 of 14 invasive
lesions; again SNAI2 expression did not correlate with
tumor stage (P  0.63). Similarly to SNAI1, expression
was restricted to cell nuclei and cytoplasm (Figure 4, E
and H). SNAI1 and SNAI2 are therefore both highly ex-
pressed in follicular carcinomas of all pathological
stages. A reduction in CDH1 expression was seen in 15
of 31 follicular cancers, 6 of 17 minimally invasive, and 10
of 14 invasive tumors (Figure 4F). Inverse correlation
between SNAI1/SNAI2 and CDH1 expression was seen
in 13 of 31 cases (9 of 17 minimally invasive and 4 of 14
invasive) in focal tumor areas. CDH1 expression is there-
fore more frequently lost in invasive compared with min-
imally invasive lesions (P  0.09). In three minimally
invasive carcinomas, SNAI1 and SNAI2 expression
Figure 4. Expression of SNAI1, SNAI2 and CDH1 in normal human thyroid tissue and follicular carcinomas. Positive reactivity is demonstrated by brown staining.
SNAI1 and SNAI2 are not expressed in normal thyroid follicles (A and B), whereas CDH1 is expressed along basolateral cell membranes (C). SNAI1 is expressed
in the nuclei and cytoplasm of thyrocytes from follicular thyroid carcinomas (D and G, arrows indicate positive nuclei), as is SNAI2 (E and H, arrows indicate
positive nuclei). CDH1 expression is markedly reduced in cells from follicular carcinomas (F and I) with nuclear SNAI1 and SNAI2 expression compared with
normal thyroid follicles. Original magnifications: 40 (A–C, G–I); 20 (D–F).
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seemed to be restricted to the invasive tumor front, with
concomitant reduced CDH1 reactivity.
Expression of SNAI1 was seen in 28 of 32 papillary
cancers (T1, n  4; T2, n  10; T3, n  4; T4, n  10).
There was no statistical difference in T1 and T2 tumors
compared with T3 and T4 cases (P  0.35). Immunore-
activity was seen in both nuclear and cytoplasmic loca-
tions, similar to follicular carcinomas (Figure 5, A and D).
SNAI2 expression was seen in all tumors analyzed, but
expression was only nuclear in location in three cases
(T2, n  1; T4, n  2) (Figure 5, B and E) and was almost
entirely cytoplasmic in nature in the other cases. CDH1
expression was reduced compared with reactivity in nor-
mal tissue in 15 of 32 papillary cancers in our series (T1,
n  2; T2, n  2; T3, n  4; T4, n  7), with loss of
expression correlating with advanced tumor stage (P 
0.063) (Figure 5, C and F). SNAI1 nuclear positivity and
reduction of CDH1 reactivity occurred in follicles of 12
tumors. In two tumors, there seemed to be increased
SNAI1 expression at the invasive tumor front, with con-
comitant reduction in CDH1 expression.
The data on papillary carcinomas prompted us to an-
alyze SNAI1 and SNAI2 expression in lymph node me-
tastases from these tumors. Of four metastases studied,
all expressed both SNAI1 and SNAI2 in nuclear and
cytoplasmic locations (Figure 5, G and H). Concomitant
with this, diffuse weak cytoplasmic CDH1 staining was
noted, but with no membrane reactivity (Figure 5I).
SNAI1 Expression in Transgenic Mice Is
Associated with Thyroid Carcinoma
Development
The data shown above demonstrate that SNAI1 and SNAI2
are ectopically expressed in both human thyroid carcinoma
cell lines and follicular and papillary thyroid cancer speci-
mens. Furthermore, SNAI1 expression in thyrocytes is as-
sociated with suppression of CDH1 transcription. On the
basis of the above results, we wished to determine whether
SNAI1 expression in transgenic mice is associated with thyroid
carcinoma development. To test this, we analyzed mice ex-
Figure 5. Expression of SNAI1, SNAI2, and CDH1 in papillary thyroid carcinomas and their lymph node metastases. Positive reactivity is demonstrated by brown
staining. SNAI1 is expressed in the nuclei and cytoplasm of both papillary carcinomas (A and D, arrows indicate positive nuclei) and their lymph node metastases
(G, arrows indicate positive nuclei), as is SNAI2 (B, E, and H; arrows indicate positive nuclei). CDH1 reactivity is reduced in cells from this carcinoma (C and F)
and its nodal metastasis (I) demonstrating nuclear SNAI1 and SNAI2 expression, compared with normal follicles. Original magnifications: 20 (A–C); 40 (D–I).
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pressing hypomorphic tetracycline-repressible SNAI1 trans-
genes that increase SNAI1 expression to 20% greater than
normal levels using the CombiTA-SNAI1 transgene. These
mice have previously been shown to develop both epithelial
and mesenchymal tumors.22 Papillary thyroid carcinomas
developed in 3 of 61 CombiTA-Snail mice analyzed (5%)
compared with 0 of 30 wild-type mice (P  0.296) (Figure
6A). Tumors developed between 7 and 11 months of age.
Cervical radiotherapy is a known risk factor for thyroid can-
cer,27 and we were therefore interested to analyze whether
the addition of radiotherapy to SNAI1 overexpression in
mice led to an increased incidence of thyroid cancer de-
velopment. Seven of 30 (23%) mice thus analyzed devel-
oped papillary carcinoma, confirming that SNAI1 overex-
pression and radiotherapy were synergistic tumorigenic
factors (Table 1). Furthermore, tumor development in these
mice was greatly accelerated, occurring between 3 and 5
months of age, and in two cases was associated with mul-
tiple lymph node metastases. The tumorigenicity of these
thyroid cancers was confirmed by injection into nude mice.
Last, we wished to assess the effect of reducing SNAI1
expression in CombiTA-Snail mice that had received radio-
therapy and developed thyroid cancer. Administering tetra-
cycline abolished SNAI1 expression, as expected (Figure
6B), with concomitant CDH1 re-expression. Tumor growth
was not retarded in any case, however, demonstrating that
tumor growth could not be reversed by inhibition of SNAI1
expression.
Discussion
This study provides the first evidence that Snail family
transcription factors are involved in thyroid carcinoma
development. First, we have shown SNAI1 and SNAI2 are
expressed in human thyroid carcinoma samples and in cell
lines derived from thyroid cancers, but not in normal thyroid
tissue or in a cell line derived from normal thyrocytes. Sec-
ond, SNAI1 is active in the ori-3 model of normal thyrocytes
as regards repression of CDH1 transcription. Third, expres-
sion of SNAI1 in mouse thyroid glands is associated with
papillary carcinoma development.
Analysis of thyroid cell lines demonstrated that SNAI1
and SNAI2 mRNA and protein were expressed in all lines
derived from thyroid carcinoma analyzed. This included
lines of papillary (B-CPAP, K1), follicular (FTC-133), and
anaplastic (CAL-62, 8305C) carcinoma origin. Interest-
ingly, however, neither SNAI1 nor SNAI2 mRNA or protein
was expressed in ori-3 cells, derived from SV-40-trans-
formed normal thyrocytes. Of note, ori-3 cells grow in a
manner representing normal thyroid follicles and retain
functional evidence of thyroid origin (iodide-trapping and
thyroglobulin production),28 whereas none of the other
lines studied adopts either a regular morphology in cul-
ture or thyroid functional characteristics. CDH1 mRNA
and protein were strongly expressed in ori-3 cells, corre-
lating with their retention of thyroid follicular function and
morphology, thus demonstrating an inverse expression to
SNAI1 and SNAI2 mRNA. The lines B-CPAP and FTC-133
Figure 6. A: Thyroid carcinoma development in CombitTA-Snail mice. His-
tological analysis of thyroid of wild type and CombitTA-Snail mice is dem-
onstrated. Representative tissue sections from wild-type and CombitTA-Snail
mice were stained with H&E. The histological section of a wild-type mouse
shows normal follicle formation, whereas the CombitTA-Snail thyroid shows
the presence of a papillary thyroid carcinoma. B: Tetracycline suppresses
SNAI1 expression in mouse thyroid glands. RT-PCR was used to analyze
CombitTA-Snail and CDH1 expression in the presence and absence of tetracy-
cline in mouse drinking water using mouse RNA derived from thyroid tissue,
with actin as a loading control. In the presence of tetracycline, there is strong
CDH1 expression, but removal of tetracycline induces SNAI1 expression, with
concomitant loss of CDH1 expression. Original magnifications, 20.
Table 1. Thyroid Carcinoma Development in CombitTA-Snail Mice
Mice
Mice
studied*
Mice with thyroid
carcinoma (%)†
Age in months
at tumor onset
Tumor
type (%)
Sex ratio
(female:male)
CombitTA-Snail 61 3 (5) 7 to 11 Papillary 2:1
CombitTA-Snail  Rx‡ 30 7 (23) 3 to 5 Papillary¶ 5:2
CombitTA-Snail  Rx  Dox 7 7 Papillary 5:2
*Number of mice during or after the period of cancer.
†Number of mice sacrificed with cancer and percentage of tumor incidence.
‡Effect of irradiation on thyroid carcinoma development in young CombitTA-Snail mice. Thirty CombitTA-Snail mice were irradiated at 400 rads to
determine thyroid carcinoma development. No thyroid carcinoma development was observed in controls irradiated with equal dosage.
Effect of Snail suppression in papillary thyroid carcinomas developed after radiation exposure. Mice were evaluated for disease progression after
administration of tetracycline (4 g/L in the drinking water for 2 weeks). This dose is sufficient to suppress exogenous Snail expression (see Figure 6).
¶Multiple nodes were detected in two cases.
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expressed CDH1 mRNA and protein weakly, whereas in
the other lines analyzed it was absent. B-CPAP cells do
show features of thyroid cells such as thyroglobulin pro-
duction,29 and FTC-133 cells have previously been
shown to express CDH1.30
We next analyzed whether SNAI1 and SNAI2 were
located in the nuclei of thyroid carcinoma cells, as may
be expected if they are active in their role as transcription
factors in this situation. In all lines analyzed, expression
was indeed predominantly nuclear in location, even in
B-CPAP and FTC-133 cells, which express both SNAI1
and SNAI2 and CDH1. It seems therefore that there must
be additional, unknown, factors inhibiting SNAI1- and
SNAI2-mediated repression of CDH1 transcription in
these two cell lines. As has already been mentioned, a
variety of other cell lines demonstrate lack of inverse
expression of SNAI1/SNAI2 and CDH1,14,16 likely repre-
senting the fact that multiple regulators of CDH1 tran-
scription exist. Consistent with the role of SNAI1 and
SNAI2 in producing a mesenchymal cell phenotype, cell
lines expressing these transcription factors did not form
cell monolayers with close cell-cell contacts. This even
included the lines B-CPAP and FTC-133, and therefore it
seems that in these lines CDH1 membranous expression
does not lead to monolayer formation in the presence of
SNAI1 and SNAI2 nuclear expression. A possible explana-
tion for this phenomenon is either posttranslational modifi-
cation of CDH1 in these cells, for example phosphorylation,
or alteration in CDH1 binding partners needed for strong
cell-cell adhesion, both of which have been shown to lead to
reduced cell-cell adhesion in vitro.31
Next, we wished to assess whether expression of
SNAI1 in thyroid cells led to transcriptional repression of
known SNAI1 target genes. The ori-3 line was selected,
as it is SNAI1- and SNAI2-negative and CDH1-positive.
CDH1 transcription is repressed by SNAI1 in cells from a
variety of tissue types,14,15 and this was therefore chosen
to analyze ability of SNAI1 to repress gene transcription
in thyrocytes. In this line, SNAI1 did indeed lead to tran-
scriptional silencing of CDH1 within 24 hours, confirming
that these cells represent a suitable thyroid-derived
model for analysis of effects of SNAI1 expression. In this
context it is interesting to note that a recent report by Rao
and colleagues32 demonstrated that treatment of FTC-
133 cells with lithium chloride led to up-regulation of
SNAI1 expression with concomitant CDH1 down-regula-
tion, agreeing with our observation that SNAI1 can mod-
ulate CDH1 expression in thyrocytes. Transfection effi-
ciencies of 70 to 80% were achieved in ori-3 cells, and it
seems that, at this level of SNAI1 expression, CDH1
transcription is too low to be detected by RT-PCR or
Western blotting of these transfected cells.
On analyzing expression of SNAI1 and SNAI2 within
follicular and papillary thyroid carcinoma specimens, it
became apparent that both transcription factors were
highly expressed in these tumor types, with nuclear and
cytoplasmic staining being apparent in most cases; how-
ever, SNAI2 demonstrated nuclear expression less com-
monly in papillary carcinomas. Yang and colleagues33
have shown that subcellular localization of SNAI1 corre-
lates with transcriptional repressive activity, and it is likely
that only nuclear transcription factor immunoreactivity
represents potentially functionally active protein in the
tumors studied. Interestingly, in a small number of tu-
mors, SNAI1 and SNAI2 immunoreactivity was most
marked at the invasive front, associated with CDH1
down-regulation. This fits with the proposed roles of
SNAI1 and SNAI2 in tumor invasion.34 For both tumor
types, there was an inverse correlation between SNAI1/
SNAI2 and CDH1 expression in some cases only. Fur-
thermore, SNAI1 and SNAI2 were both expressed in
lymph node metastases from papillary carcinomas. This
suggests that ectopic expression of these transcription
factors occurs early on in the neoplastic process, being
present in microfoci of papillary carcinoma and minimally
invasive follicular carcinomas, with expression being
maintained through to invasive carcinoma and lympho-
matous metastases. In agreement with previous obser-
vations in mice overexpressing SNAI1 and SNAI2,22,35
these observations indicate SNAI1/SNAI2 can participate
in both tumor formation and dissemination during tumor
metastasis.
The coexpression of SNAI1 and SNAI2 in thyroid carci-
nomas raises the question as to whether one or other tran-
scription factor shows dominant activity in tumor cells. From
the data presented here, it cannot be shown that either
factor is active in thyroid tumors in vivo, although nuclear
localization of the transcription factors is suggestive of func-
tionality. Recent evidence demonstrates that SNAI1 and
SNAI2 regulate expression of both overlapping and unique
genes in an in vitro model36 and perform different roles
during breast cancer progression.34
The above experiments provided circumstantial evi-
dence that SNAI1 and SNAI2 may be involved in thyroid
carcinogenesis. We wished, however, to obtain more
direct proof of any link. SNAI1 demonstrated nuclear
localization more commonly than SNAI2 from our immu-
nohistochemical data, and therefore we chose to concen-
trate on SNAI1 in further experiments. We have previously
shown that CombiTA-Snail mice develop a range of epi-
thelial and mesenchymal tumors not seen in wild-type
mice, with concordant increased SNAI1 expression in a
variety of tissues. This therefore was chosen as a model
to assess whether SNAI1 expression led to thyroid car-
cinomas in vivo. We first confirmed that SNAI1 RNA was
present in thyroid glands from Combi-TA mice (Figure
6B) and absent from wild-type mice (not shown). SNAI1
expression was associated with repression of CDH1 tran-
scription in the thyroid (Figure 6B). Thyroid carcinoma
development was then assessed in both wild-type and
Combi-TA mice. As has been seen, papillary thyroid car-
cinomas developed in 3 of 61 CombiTA-Snail mice ana-
lyzed (5%) compared with 0 of 30 wild-type mice, pro-
viding a direct link between SNAI1 expression in the
thyroid and papillary carcinoma development. Of inter-
est, irradiation led to an increased rate of tumor develop-
ment, which also occurred at an earlier age. Furthermore,
once thyroid carcinoma had developed, repression of
SNAI1 in the thyroid gland to undetectable levels (Figure
6B) did not arrest tumor development, demonstrating that
SNAI1 down-regulation does not prevent established tu-
mor growth.
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In conclusion, we have demonstrated that SNAI1 and
SNAI2 are highly expressed in human thyroid carcinomas
and cell lines derived thereof, and SNAI1 expression in
mouse thyroid glands is associated with papillary carci-
noma development.
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